Literature DB >> 8145050

Production of interleukin 10 by islet cells accelerates immune-mediated destruction of beta cells in nonobese diabetic mice.

L Wogensen1, M S Lee, N Sarvetnick.   

Abstract

The T helper type 2 (Th2) cell product interleukin 10 (IL-10) inhibits the proliferation and function of Th1 lymphocytes and macrophages (M phi). The nonobese diabetic mouse strain (NOD/Shi) develops a M phi and T cell-dependent autoimmune diabetes that closely resembles human insulin-dependent diabetes mellitus (IDDM). The objective of the present study was to explore the consequences of localized production of IL-10 on diabetes development in NOD/Shi mice. Surprisingly, local production of IL-10 accelerated the onset and increased the prevalence of diabetes, since diabetes developed at 5-10 wk of age in 92% of IL-10 positive I-A beta g7/g7, I-E- mice in first (N2) and second (N3) generation backcrosses between IL-10 transgenic BALB/c mice and (NOD/Shi) mice. None of the IL-10 negative major histocompatibility complex-identical littermates were diabetic at this age. Furthermore, diabetes developed in 33% of I-A beta g7/d, I-E+ N3 mice in the presence of IL-10 before the mice were 10 wk old. Our findings support the notion that IL-10 should not simply be regarded as an immunoinhibitory cytokine, since it possesses powerful, immunostimulatory properties as well. Furthermore, our observations suggest that beta cell destruction in NOD mice may be a Th2-mediated event.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8145050      PMCID: PMC2191460          DOI: 10.1084/jem.179.4.1379

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  31 in total

1.  IL-10: a novel cytotoxic T cell differentiation factor.

Authors:  W F Chen; A Zlotnik
Journal:  J Immunol       Date:  1991-07-15       Impact factor: 5.422

2.  Genetic control of diabetogenesis in NOD/Lt mice. Development and analysis of congenic stocks.

Authors:  M Prochazka; D V Serreze; S M Worthen; E H Leiter
Journal:  Diabetes       Date:  1989-11       Impact factor: 9.461

3.  Direct evidence for the contribution of the unique I-ANOD to the development of insulitis in non-obese diabetic mice.

Authors:  T Miyazaki; M Uno; M Uehira; H Kikutani; T Kishimoto; M Kimoto; H Nishimoto; J Miyazaki; K Yamamura
Journal:  Nature       Date:  1990-06-21       Impact factor: 49.962

4.  Prevention of insulin-dependent diabetes mellitus in non-obese diabetic mice by transgenes encoding modified I-A beta-chain or normal I-E alpha-chain.

Authors:  T Lund; L O'Reilly; P Hutchings; O Kanagawa; E Simpson; R Gravely; P Chandler; J Dyson; J K Picard; A Edwards
Journal:  Nature       Date:  1990-06-21       Impact factor: 49.962

5.  Development of autoimmune insulitis is prevented in E alpha d but not in A beta k NOD transgenic mice.

Authors:  M Uehira; M Uno; T Kürner; H Kikutani; K Mori; T Inomoto; T Uede; J Miyazaki; H Nishimoto; T Kishimoto
Journal:  Int Immunol       Date:  1989       Impact factor: 4.823

6.  Prevention of autoimmune insulitis by expression of I-E molecules in NOD mice.

Authors:  H Nishimoto; H Kikutani; K Yamamura; T Kishimoto
Journal:  Nature       Date:  1987 Jul 30-Aug 5       Impact factor: 49.962

7.  Three recessive loci required for insulin-dependent diabetes in nonobese diabetic mice.

Authors:  M Prochazka; E H Leiter; D V Serreze; D L Coleman
Journal:  Science       Date:  1987-07-17       Impact factor: 47.728

8.  Genetic analysis of diabetes in the nonobese diabetic mouse. I. MHC and T cell receptor beta gene expression.

Authors:  A Livingstone; C T Edwards; J A Shizuru; C G Fathman
Journal:  J Immunol       Date:  1991-01-15       Impact factor: 5.422

9.  IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells.

Authors:  D F Fiorentino; A Zlotnik; P Vieira; T R Mosmann; M Howard; K W Moore; A O'Garra
Journal:  J Immunol       Date:  1991-05-15       Impact factor: 5.422

10.  Prevention of diabetes in non-obese diabetic I-Ak transgenic mice.

Authors:  R M Slattery; L Kjer-Nielsen; J Allison; B Charlton; T E Mandel; J F Miller
Journal:  Nature       Date:  1990-06-21       Impact factor: 49.962

View more
  55 in total

1.  Interleukin 10 treatment for rheumatoid arthritis.

Authors:  E W St Clair
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 2.  Immunotherapy of immune-mediated diabetes. Present and future.

Authors:  N Maclaren
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

Review 3.  Immune mechanisms that regulate susceptibility to autoimmune type I diabetes.

Authors:  B Singh; T L Delovitch
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

Review 4.  Type I (insulin-dependent) diabetes is a Th1- and Th2-mediated autoimmune disease.

Authors:  S T Azar; H Tamim; H N Beyhum; M Z Habbal; W Y Almawi
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

Review 5.  Prospects for the prevention and reversal of type 1 diabetes mellitus.

Authors:  Nikolai Petrovsky; Diego Silva; Desmond A Schatz
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 6.  Cytokine-based immunointervention in the treatment of autoimmune diseases.

Authors:  L Adorini
Journal:  Clin Exp Immunol       Date:  2003-05       Impact factor: 4.330

Review 7.  Current status of gene delivery and gene therapy in lacrimal gland using viral vectors.

Authors:  Shivaram Selvam; Padmaja B Thomas; Sarah F Hamm-Alvarez; Joel E Schechter; Douglas Stevenson; Austin K Mircheff; Melvin D Trousdale
Journal:  Adv Drug Deliv Rev       Date:  2006-09-15       Impact factor: 15.470

8.  Production of interleukin (IL)-5 and IL-10 accompanies T helper cell type 1 (Th1) cytokine responses to a major thyroid self-antigen, thyroglobulin, in health and autoimmune thyroid disease.

Authors:  C H Nielsen; L Hegedüs; K Rieneck; A C Moeller; R G Q Leslie; K Bendtzen
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

Review 9.  CD28/B7 regulation of autoimmune diabetes.

Authors:  K G Herold; D J Lenschow; J A Bluestone
Journal:  Immunol Res       Date:  1997-02       Impact factor: 2.829

Review 10.  Interleukin-10 paradox: A potent immunoregulatory cytokine that has been difficult to harness for immunotherapy.

Authors:  Ankit Saxena; Sam Khosraviani; Sanjeev Noel; Divya Mohan; Thomas Donner; Abdel Rahim A Hamad
Journal:  Cytokine       Date:  2014-12-04       Impact factor: 3.861

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.